Authors: LEMM G KUPPERS J FREY R WINGENDER W KUHLMANN J

Citation: G. Lemm et al., MONITORING OF PROTEINURIA IN PHASE-I STUDIES IN HEALTHY MALE-SUBJECTS, European Journal of Clinical Pharmacology, 54(4), 1998, pp. 287-294

Authors: MUCK W RITTER W OCHMANN K UNGER S AHR G WINGENDER W KUHLMANN J

Citation: W. Muck et al., ABSOLUTE AND RELATIVE BIOAVAILABILITY OF THE HMG-COA REDUCTASE INHIBITOR CERIVASTATIN, International journal of clinical pharmacology and therapeutics, 35(6), 1997, pp. 255-260

Authors: DIETRICH H RITTER W WINGENDER W UNGER S OCHMANN K

Citation: H. Dietrich et al., CERIVASTATIN - A NEW HMG-COA REDUCTASE INHIBITOR - IN COMBINATION WITH THE ANTACID MAALOX(R) - AN INVESTIGATION OF THE SAFETY AND PHARMACOKINETICS, Atherosclerosis, 130, 1997, pp. 101-101

Authors: FREY R RITTER W UNGER S OCHMANN K WINGENDER W

Citation: R. Frey et al., PHASE-I STUDY TO INVESTIGATE THE EFFECTS OF CIMETIDINE ON THE PHARMACOKINETICS OF CERIVASTATIN - A NEW HMG-COA REDUCTASE INHIBITOR, Atherosclerosis, 130, 1997, pp. 103-103